InChI=1S/C22H32O4/c1- 2- 3- 10- 15- 20(23) 17- 12- 8- 9- 13- 18- 21(24) 16- 11- 6- 4- 5- 7- 14- 19- 22(25) 26/h3,5- 13,17- 18,20- 21,23- 24H,2,4,14- 16,19H2,1H3,(H,25,26) /b7- 5- ,9- 8+,10- 3- ,11- 6- ,17- 12- ,18- 13+/t20- ,21- /m1/s1 |
CRDZYJSQHCXHEG-HBMALMRFSA-N |
OC(CC/C=C\C/C=C\C[C@H](/C=C/C=C/C=C\[C@@H](C/C=C\CC)O)O)=O |
|
Bronsted acid
A molecular entity capable of donating a hydron to an acceptor (Bronsted base).
(via oxoacid )
|
|
specialised pro-resolving mediator
A class of cell signaling molecules enzymatically derived from n-3 long chain polyunsaturated fatty acids that have important roles in orchestrating the resolution of tissue inflammation.
human xenobiotic metabolite
Any human metabolite produced by metabolism of a xenobiotic compound in humans.
|
|
specialised pro-resolving mediator
A class of cell signaling molecules enzymatically derived from n-3 long chain polyunsaturated fatty acids that have important roles in orchestrating the resolution of tissue inflammation.
anti-inflammatory agent
Any compound that has anti-inflammatory effects.
neuroprotective agent
Any compound that can be used for the treatment of neurodegenerative disorders.
|
|
View more via ChEBI Ontology
(4Z,7Z,10R,11E,13E,15Z,17R,19Z)- 10,17- dihydroxydocosa- 4,7,11,13,15,19- hexaenoic acid
|
(4Z,7Z,10R,11E,13E,15Z,17R,19Z)- 10,17- dihydroxydocosahexaenoic acid
|
ChEBI
|
10(R),17(R)- dihydroxydocosa- 4Z,7Z,11E,13E,15Z,19Z- hexaenoic acid
|
ChEBI
|
aspirin-triggered neuroprotectin D1
|
ChEBI
|
AT-(NPD1/PD1)
|
ChEBI
|
AT-NPD1
|
ChEBI
|
AT-PD1
|
ChEBI
|
22110134
|
Reaxys Registry Number
|
Reaxys
|
21867913
|
PubMed citation
|
Europe PMC
|
22542947
|
PubMed citation
|
Europe PMC
|
22566962
|
PubMed citation
|
Europe PMC
|
22690022
|
PubMed citation
|
Europe PMC
|
24262603
|
PubMed citation
|
Europe PMC
|
24520010
|
PubMed citation
|
Europe PMC
|
25139562
|
PubMed citation
|
Europe PMC
|
27121596
|
PubMed citation
|
Europe PMC
|
|